Condition: Refractory Diffuse Large B Cell Lymphoma (DLBCL) · Relapsed Diffuse Large B Cell Lymphoma · High Grade B-cell Lymphoma (HGBCL) · Sponsor: Miltenyi Biomedicine GmbH
DALY II USA is a phase II, multi-center, single arm study to evaluate the efficacy, safety, and pharmacokinetics of zamtocabtagene autoleucel (MB-CART2019.1) in patients with relapsed and/or refractory B cell lymphoma (BCL). Cohorts include subjects with diffuse large B-cell lymphoma (DLBCL) after receiving at least 2 lines of therapy, primary or secondary central nervous system (CNS) lymphoma (PCNSL) and (SCNSL) after receiving at least one line of therapy, mantle cell lymphoma (MCL) and Richter's transformation (RT) after receiving at least one line of therapy, and DLBCL transplant-ineligible after receiving at least one line of therapy.
This description comes directly from the study's public registry record.
Ron Gomez · 617-218-0044 · clinicaltrials@miltenyi.com
Harshita Gahankari · 617-218-0044 · clinicaltrials@miltenyi.com
Always discuss trial participation with your own doctor first.
| University of Alabama at Birmingham | Birmingham, Alabama, United States | Recruiting |
| Banner MD Anderson Cancer Center | Gilbert, Arizona, United States | Recruiting |
| Mayo Clinic | Phoenix, Arizona, United States | Recruiting |
| UC San Diego Health | La Jolla, California, United States | Recruiting |
| Stanford University | Stanford, California, United States | Recruiting |
| Colorado Blood Cancer Institute | Denver, Colorado, United States | Recruiting |
| Yale University | New Haven, Connecticut, United States | Recruiting |
| Baptist Health Miami Cancer Institute | Miami, Florida, United States | Recruiting |
| Winship Cancer Institute of Emory University | Atlanta, Georgia, United States | Recruiting |
| Georgia Cancer Center at Augusta University | Augusta, Georgia, United States | Recruiting |
| Robert H Lurie Cancer Center | Chicago, Illinois, United States | Recruiting |
| University of Kansas Cancer Center | Westwood, Kansas, United States | Recruiting |
+ 20 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04792489